Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AMLX
DateTimeSourceHeadlineSymbolCompany
25/09/202422:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
16/09/202422:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/09/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
28/08/202413:30Business WireAmylyx Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
26/08/202423:49Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
12/08/202414:00Business WireAmylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and NeurodegenerationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/202412:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/202412:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/08/202412:00Business WireAmylyx Pharmaceuticals Reports Second Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/08/202414:00Business WireAmylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/08/202414:00Business WireAmylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
19/07/202400:00PR Newswire (US)Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/07/202412:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/07/202412:00Business WireAmylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy DesignationNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/07/202421:01Business WireAmylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of AvexitideNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/06/202421:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/06/202421:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
07/06/202421:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
06/06/202421:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
04/06/202414:00Business WireAmylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
17/05/202400:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/05/202412:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/05/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/05/202412:00Business WireAmylyx Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/05/202414:00Business WireAmylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/05/202414:00Business WireAmylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
10/04/202414:00Business WireAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeNASDAQ:AMLXAmylyx Pharmaceuticals Inc
09/04/202410:45PR Newswire (US)The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
08/04/202414:00Business WireAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024NASDAQ:AMLXAmylyx Pharmaceuticals Inc
05/04/202410:45PR Newswire (US)Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLXNASDAQ:AMLXAmylyx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMLX

Your Recent History

Delayed Upgrade Clock